NIH’s $577M Award Stirs Creative Biolabs in COVID-19 Antiviral Drug Discovery

June 20 16:15 2022
Encouraged by the report that NIH awards a total of $577M for antiviral drug developers, the prestigious CRO, Creative Biolabs, is determined to enhance their anti-SARS-CoV-2 drug discovery services to better aid antiviral drug developers.

New York, USA – June 20, 2022 – The recent uplifting news reported that the National Institute of Allergy and Infectious Diseases (NIAID) awarded a total of $577M to establish 9 Antiviral Drug Discovery (AViDD) Centers for pathogens of pandemic concern. It’s a further recognition and encouragement for researchers who have long engaged in fighting against the COVID-19 pandemic. Creative Biolabs, a behind-the-scenes service provider for drug discovery and vaccine development, remains passionate about its services and is determined to better support research for COVID-19 antiviral candidates and related antivirals against other viral families that have the potential to cause a future pandemic.

Drug discovery services at Creative Biolabs for SARS-CoV-2 are primarily focused on the early-stage discovery, identification, and validation of SARS-CoV-2 drug candidates, as well as the design, analysis, qualification, and optimization of SARS-CoV-2 vaccines. Some featured solutions include:

Virus-like Particles Based Vaccine Development

“Virus-like particles (VLPs) are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but they lack the viral genome. So they may produce safer and cheaper vaccine candidates.” States a scientist at Creative Biolabs.

Having mastered several VLP expression systems, such as mammalian cells (293T, CHO), yeast, recombinant vaccinia virus, and baculovirus expression systems, Creative Biolabs proposes additional services for VLP-based SARS-CoV-2 vaccine development, including the genetic engineering techniques designed to improve the immunogenicity of VLP. Besides, some SARS-CoV-2 VLPs have already been successfully developed and are available for production.

Therapeutic Human Monoclonal Antibodies Development

The structural spike proteins (S) of SARS-CoV-2 are key to infectivity and pathogenicity, and thus are indicated as an effective target for neutralizing antibodies (nAbs) for prophylaxis and early treatment of emerging viral pathogens. Researchers can develop SARS-CoV-2 therapeutic human mAbs leveraging antibodies from either COVID-19 recovered patients’ sera or SARS-CoV-2 surface protein immunized humanized mice. Currently, Creative Biolabs provides monoclonal antibody screening services based on these two main strategies.

Extensive antibody development and manufacturing experiences also enable Creative Biolabs to develop neutralizing antibodies through different subjects, such as CR3022, CD4, and Glycoprotein.

Cytopathic Effect (CPE) Assay for Antiviral Drug Evaluation

Creative Biolabs has established a series of evaluation platforms for SARS-CoV-2 drugs, based on which the SARS-CoV-2 CPE assay service is highlighted because it can be applied not only in the drug antiviral effect investigation but also in methodology research of viral growth, titration, and neutralization of SARS-CoV-2.

About Creative Biolabs

Creative Biolabs ( is a biotech company specializing in drug discovery and vaccine development. It has contributed a lot to the research and control of coronavirus pneumonia during the MERS epidemic in 2012. Thus, this company remains a pioneering force when the COVID-19 pandemic broke out in 2019. In addition to comprehensive services that enhance the development of antiviral drugs and vaccines, Creative Biolabs also proves its global competitiveness through high-quality recombinant proteins, antibodies, test kits, and other products.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States